rs35352891

Variant summary

Our verdict is Benign. The variant received -15 ACMG points: 2P and 17B. PM1BP4_StrongBP6_Very_StrongBS1BS2_Supporting

The NM_001048174.2(MUTYH):​c.1034C>T​(p.Ala345Val) variant causes a missense change. The variant allele was found at a frequency of 0.000208 in 1,614,186 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A345T) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00020 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00021 ( 6 hom. )

Consequence

MUTYH
NM_001048174.2 missense

Scores

10
9

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts P:1U:1B:14

Conservation

PhyloP100: 6.96

Publications

38 publications found
Variant links:
Genes affected
MUTYH (HGNC:7527): (mutY DNA glycosylase) This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2017]
MUTYH Gene-Disease associations (from GenCC):
  • familial adenomatous polyposis 2
    Inheritance: AD, AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen, G2P
  • colorectal cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
  • familial ovarian cancer
    Inheritance: AD, AR Classification: NO_KNOWN Submitted by: ClinGen
  • hereditary breast carcinoma
    Inheritance: AD, AR Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -15 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 24 benign, 52 uncertain in NM_001048174.2
BP4
Computational evidence support a benign effect (MetaRNN=0.009427875).
BP6
Variant 1-45331729-G-A is Benign according to our data. Variant chr1-45331729-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 41751.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population eas. GnomAdExome4 allele frequency = 0.000209 (305/1461828) while in subpopulation EAS AF = 0.00625 (248/39700). AF 95% confidence interval is 0.00561. There are 6 homozygotes in GnomAdExome4. There are 159 alleles in the male GnomAdExome4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAdExome4 at 6 AD,AR geneVariant has number of homozygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MUTYHNM_001048174.2 linkc.1034C>T p.Ala345Val missense_variant Exon 12 of 16 ENST00000456914.7 NP_001041639.1 Q9UIF7-6

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MUTYHENST00000456914.7 linkc.1034C>T p.Ala345Val missense_variant Exon 12 of 16 1 NM_001048174.2 ENSP00000407590.2 Q9UIF7-6
ENSG00000288208ENST00000671898.1 linkn.1622C>T non_coding_transcript_exon_variant Exon 16 of 21 ENSP00000499896.1 A0A5F9ZGZ0

Frequencies

GnomAD3 genomes
AF:
0.000197
AC:
30
AN:
152240
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00500
Gnomad SAS
AF:
0.000414
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000383
AC:
96
AN:
250472
AF XY:
0.000376
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00462
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.000164
GnomAD4 exome
AF:
0.000209
AC:
305
AN:
1461828
Hom.:
6
Cov.:
33
AF XY:
0.000219
AC XY:
159
AN XY:
727220
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33480
American (AMR)
AF:
0.0000224
AC:
1
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00625
AC:
248
AN:
39700
South Asian (SAS)
AF:
0.000394
AC:
34
AN:
86258
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53364
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.0000108
AC:
12
AN:
1112002
Other (OTH)
AF:
0.000166
AC:
10
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.494
Heterozygous variant carriers
0
22
44
65
87
109
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000197
AC:
30
AN:
152358
Hom.:
0
Cov.:
33
AF XY:
0.000295
AC XY:
22
AN XY:
74506
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41590
American (AMR)
AF:
0.0000653
AC:
1
AN:
15310
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00502
AC:
26
AN:
5184
South Asian (SAS)
AF:
0.000414
AC:
2
AN:
4828
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000147
AC:
1
AN:
68030
Other (OTH)
AF:
0.00
AC:
0
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.488
Heterozygous variant carriers
0
2
4
5
7
9
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000397
Hom.:
0
Bravo
AF:
0.000344
ExAC
AF:
0.000379
AC:
46
Asia WGS
AF:
0.00231
AC:
8
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Pathogenic:1Uncertain:1Benign:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Familial adenomatous polyposis 2 Pathogenic:1Benign:4
May 28, 2019
Mendelics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 18, 2016
Counsyl
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

The MUTYH p.Ala373Val variant was identified in 4 of 256 proband chromosomes (frequency: 0.016) from Japanese or Korean individuals or families with adenomatous polyposis, and was identified in 4 of 192 control chromosomes (frequency: 0.021) from healthy individuals (Kim 2007; Yanaru-Fujisawa 2008); however, an insufficient number of controls were included in these studies to determine the frequency of this variant in the general population. Functional studies assessing glycosylase activity of the MUTYH protein showed that the p.Ala373Val variant retained its activity (Goto 2010, Yanaru-Fujisawa 2008). The variant was also identified in dbSNP (rs35352891) “With allele of uncertain significance”, with a minor allele frequency of 0.001(1000 Genomes Project), HGMD, and the ClinVar database (as a variant of unknown significance). The p.Ala373 residue is conserved in mammals; however, computational analyses (PolyPhen-2, SIFT, AlignGVGD, MutationTaster) provide inconsistent predictions regarding the impact to the protein and this information is not very predictive of pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as predicted benign. -

Oct 08, 2019
GeneReviews
Significance:Pathogenic
Review Status:flagged submission
Collection Method:literature only

- -

Hereditary cancer-predisposing syndrome Uncertain:1Benign:3
Mar 21, 2016
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 14, 2017
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.
Significance:Uncertain significance
Review Status:flagged submission
Collection Method:clinical testing

- -

May 16, 2021
Sema4, Sema4
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:curation

- -

Jun 11, 2018
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

not specified Benign:3
Mar 04, 2025
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 20, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Apr 18, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: MUTYH c.1118C>T (p.Ala373Val) results in a non-conservative amino acid change located in the MutY, C-terminal domain (IPR029119) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0004 in 250664 control chromosomes, predominantly at a frequency of 0.0046 within the East Asian subpopulation in the gnomAD database. The frequency within the East Asian subpopulation is equal to the estimated maximal expected allele frequency for a pathogenic variant in MUTYH causing MUTYH-Associated Polyposis (0.0046). In addition, the variant was found at an even higher frequency of 0.0091 in Japanese controls in the HGVD-Kyoto database, suggesting that this variant is a benign polymorphism found primarily in individuals of East Asian ethnicity. c.1118C>T has been reported in affected individuals in the literature, including at least one occurrence in an individual presenting with colorectal polyposis, who was homozygous for both the variant of interest, but also the likely pathogenic variant p.G272E (Yanaru-Fujisawa_2008). Cosegregation studies associating the variant of interest with disease have not, to our knowledge, been performed. Additionally, a case-control study showed the variant at a similar frequency in cases compared to controls, showing the variant to not be associated with colorectal cancer risk in the Japanese cohort (Fujita_2020). The reports in patients in the literature do not provide unequivocal conclusions about association of the variant with MUTYH-Associated Polyposis. At least two publications report experimental evidence indicating that the variant does not significantly affect DNA-glycosylase activity (e.g. Goto_2010, Yanaru-Fujisawa_2008). Multiple clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 with conflicting assessments (benign/likely benign, n=9; uncertain significance, n=2; pathogenic, n=1). Based on the evidence outlined above, the variant was classified as likely benign. -

not provided Benign:3
Jan 25, 2022
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

MUTYH: BS3:Supporting, BS2 -

Jan 02, 2024
Biesecker Lab/Clinical Genomics Section, National Institutes of Health
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:research

This variant has been classified as likely benign based on a combination of factors including bioinformatic predictions (REVEL 0.470), population frequency in gnomAD (popmax EAS 0.456), and functional assay results (PMID: 20848659). -

MUTYH-related disorder Benign:1
Mar 28, 2019
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.14
BayesDel_addAF
Benign
-0.17
T
BayesDel_noAF
Uncertain
-0.010
CADD
Benign
22
DANN
Uncertain
1.0
DEOGEN2
Benign
0.11
.;.;.;.;.;T;.;.;.;T
Eigen
Uncertain
0.34
Eigen_PC
Uncertain
0.42
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.90
.;D;.;D;D;D;D;D;D;D
M_CAP
Benign
0.084
D
MetaRNN
Benign
0.0094
T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
0.27
D
MutationAssessor
Uncertain
2.6
.;.;.;.;.;M;.;.;.;.
PhyloP100
7.0
PrimateAI
Benign
0.45
T
PROVEAN
Benign
-2.3
N;N;N;N;N;N;N;N;N;.
REVEL
Uncertain
0.47
Sift
Benign
0.11
T;T;T;D;T;D;T;T;T;.
Sift4G
Uncertain
0.043
D;T;D;D;D;T;T;T;T;T
Polyphen
0.086, 0.64, 0.51
.;.;.;.;.;B;P;.;P;.
Vest4
0.56
MVP
0.94
MPC
0.22
ClinPred
0.12
T
GERP RS
5.7
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.19
gMVP
0.48
Mutation Taster
=67/33
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs35352891; hg19: chr1-45797401; COSMIC: COSV58344165; COSMIC: COSV58344165; API